Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.4269/ajtmh.20-1240

http://scihub22266oqcxt.onion/10.4269/ajtmh.20-1240
suck pdf from google scholar
33009770!7695108!33009770
unlimited free pdf from europmc33009770    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33009770&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid33009770      Am+J+Trop+Med+Hyg 2020 ; 103 (6): 2419-2428
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo #MMPMID33009770
  • Nachega JB; Ishoso DK; Otokoye JO; Hermans MP; Machekano RN; Sam-Agudu NA; Bongo-Pasi Nswe C; Mbala-Kingebeni P; Madinga JN; Mukendi S; Kolie MC; Nkwembe EN; Mbuyi GM; Nsio JM; Mukeba Tshialala D; Tshiasuma Pipo M; Ahuka-Mundeke S; Muyembe-Tamfum JJ; Mofenson L; Smith G; Mills EJ; Mellors JW; Zumla A; Mavungu Landu DJ; Kayembe JM
  • Am J Trop Med Hyg 2020[Dec]; 103 (6): 2419-2428 PMID33009770show ga
  • Little is known about the clinical features and outcomes of SARS-CoV-2 infection in Africa. We conducted a retrospective cohort study of patients hospitalized for COVID-19 between March 10, 2020 and July 31, 2020 at seven hospitals in Kinshasa, Democratic Republic of the Congo (DRC). Outcomes included clinical improvement within 30 days (primary) and in-hospital mortality (secondary). Of 766 confirmed COVID-19 cases, 500 (65.6%) were male, with a median (interquartile range [IQR]) age of 46 (34-58) years. One hundred ninety-one (25%) patients had severe/critical disease requiring admission in the intensive care unit (ICU). Six hundred twenty patients (80.9%) improved and were discharged within 30 days of admission. Overall in-hospital mortality was 13.2% (95% CI: 10.9-15.8), and almost 50% among those in the ICU. Independent risk factors for death were age < 20 years (adjusted hazard ratio [aHR] = 6.62, 95% CI: 1.85-23.64), 40-59 years (aHR = 4.45, 95% CI: 1.83-10.79), and >/= 60 years (aHR = 13.63, 95% CI: 5.70-32.60) compared with those aged 20-39 years, with obesity (aHR = 2.30, 95% CI: 1.24-4.27), and with chronic kidney disease (aHR = 5.33, 95% CI: 1.85-15.35). In marginal structural model analysis, there was no statistically significant difference in odds of clinical improvement (adjusted odds ratio [aOR] = 1.53, 95% CI: 0.88-2.67, P = 0.132) nor risk of death (aOR = 0.65, 95% CI: 0.35-1.20) when comparing the use of chloroquine/azithromycin versus other treatments. In this DRC study, the high mortality among patients aged < 20 years and with severe/critical disease is of great concern, and requires further research for confirmation and targeted interventions.
  • |*Pandemics[MESH]
  • |Adolescent[MESH]
  • |Adult[MESH]
  • |Asymptomatic Diseases[MESH]
  • |Azithromycin/therapeutic use[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |COVID-19/diagnosis/*epidemiology/*mortality[MESH]
  • |Chloroquine/therapeutic use[MESH]
  • |Democratic Republic of the Congo/epidemiology[MESH]
  • |Drug Combinations[MESH]
  • |Enoxaparin/therapeutic use[MESH]
  • |Female[MESH]
  • |Hospital Mortality/*trends[MESH]
  • |Hospitalization/statistics & numerical data[MESH]
  • |Hospitals[MESH]
  • |Humans[MESH]
  • |Intensive Care Units[MESH]
  • |Lopinavir/therapeutic use[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Obesity/diagnosis/physiopathology/virology[MESH]
  • |Patient Discharge/statistics & numerical data[MESH]
  • |Renal Insufficiency, Chronic/diagnosis/physiopathology/virology[MESH]
  • |Retrospective Studies[MESH]
  • |Risk Factors[MESH]
  • |Ritonavir/therapeutic use[MESH]
  • |SARS-CoV-2/*pathogenicity[MESH]
  • |Severity of Illness Index[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box